News related to
beyond

South Korea’s consumer prices rose 2.2 per cent in March from a year earlier, quickening from 2.0 per cent in both January and February as higher energy costs fed through the economy and kept inflation above the Bank of Korea’s medium-term 2 per cent target. The increase was milder than market expectations for 2.4 per cent, but it still marked the fastest annual pace since December and underscored the strain created by elevated crude prices linked to conflict-driven instability in the Middle East.

On a monthly basis, consumer prices rose 0.3 per cent in March, matching February’s pace. Petroleum products were a major driver even after Seoul introduced emergency measures to curb the blow to households and businesses. Government controls on fuel prices helped limit the pass-through, yet petroleum product prices still rose sharply from the previous month, showing how external energy shocks are overpowering domestic stabilisation efforts.

The inflation print matters because it lands at a moment when policymakers are trying to balance stronger export-led growth against mounting imported price pressures. The Bank of Korea said in its February outlook that consumer-price inflation for 2026 was expected to average 2.2 per cent, slightly above its previous 2.1 per cent forecast. That projection was made before the latest oil surge intensified, leaving economists to question whether the central bank’s assumptions have already been overtaken by events.

Core inflation, which strips out volatile food and energy items, eased slightly to 2.2 per cent in March from 2.3 per cent in February. That suggests underlying domestic demand pressures remain contained, even as headline inflation is being pushed up by imported costs. Another closely watched measure, which excludes agricultural products and petroleum, had been running at 2.5 per cent in February, indicating that sticky service-sector and household spending components have not fully disappeared.

Food prices offered some relief. Agricultural product prices fell in March as supply conditions improved, helping offset part of the jump in fuel-linked costs. That softer food picture helped explain why the overall figure came in below forecasts despite the energy shock. Still, analysts say the cushion from better farm output may prove temporary if transport, fertiliser and logistics costs keep climbing with oil.

South Korea is especially exposed because of its dependence on imported energy. About 70 per cent of its crude oil imports come from the Middle East, leaving the country vulnerable whenever shipping routes or production in the region come under threat. The government has already floated wider demand-management steps, including possible driving curbs beyond the public sector if crude prices climb further, a sign of how seriously officials are treating the supply risk.

Seoul has also moved on the fiscal side. This week the government proposed a supplementary budget of 26.2 trillion won, or about $17.3 billion, aimed at cushioning the economy from the oil shock and supporting low-income households and affected businesses. Of that, 10.1 trillion won is earmarked for measures tied to surging oil prices, including support for refiners operating under the emergency pricing system. The package highlights concern that inflation and slower consumption could combine to weaken the broader recovery.

For the central bank, the March data complicate an already delicate policy setting. The Bank of Korea’s next rate decision is due on April 10. Policymakers had held rates steady in February, and the latest inflation reading, while lower than forecast, is unlikely to offer much comfort because upside risks remain tied to oil, the exchange rate and transport costs. At the same time, softer core inflation argues against an aggressive response unless the energy shock broadens into wages and services.

The Orange Dot Award is a benchmark of excellence in the pet industry, established by a panel of elite American experts, including the former president of the American Pet Products Association (APPA). It recognizes products that push the boundaries of safety, innovation, and nutritional science. This year, the spotlight shines on MR.VET’s commitment to “Precision Healthcare.”​

A Biotech Breakthrough: The T-Series Revolution​

The award-winning entry, MR.VET’s T-Series, represents a paradigm shift in how pet owners approach feline health. Unlike conventional dry kibble, the T-Series—comprising T1 (Intestinal Care), T2 (Skin and Coat Care), T3 (Urinary Health), and T4 (Indoor Cat)—is built on a foundation of advanced biotechnology.​

At the heart of this innovation is MR.VET’s Specialized Freeze-Drying Technology. While traditional high-heat processing often destroys delicate bioactive compounds, MR.VET utilizes low-temperature dehydration. This “Bioactive Retention” process locks in original nutrition, ensuring that proteins, fatty acids, and essential micronutrients remain intact for efficient absorption. By combining this technology with customized nutritional profiles, MR.VET offers a tailored solution to the most common health “pain points” faced by modern pet owners.​

Certified Market Dominance: The Number One Choice​

MR.VET’s scientific accolades are backed by staggering commercial success. According to a recent market position statement by the world-renowned consulting firm Frost & Sullivan, MR.VET has been officially certified as the “Ranked No. 1 in Southeast Asia by Sales Volume of Dry Cat Food in 2025.”​

Frost & Sullivan, a global leader in market research for over 60 years, conducted an exhaustive analysis of the Southeast Asian landscape, confirming MR.VET’s status as the undisputed market leader. Over the past year, the brand has witnessed an explosive growth trajectory across both digital and physical storefronts:​

1. Indonesia: Ranked #1 on both TikTok and Shopee.​
2. Vietnam: Ranked #1 on TikTok and #3 on Shopee.​
3. Thailand: Recognized as a Top 10 TikTok Trending Brand.​
4. Regional Reach: Rapidly becoming the preferred choice for consumers in Malaysia and the Philippines.​

Double Victory: Bite of Wild Sweeps Nutrition Category​

The Orange Dot Award ceremony also celebrated a second victory for the group, as sister brand Bite of Wild secured the award in the Nutrition Category for its 42 Series.​

The inspiration for Bite of Wild began with a personal mission by co-founder Steve Bui. As a devoted pet owner, Steve sought to create a diet that truly honored the “obligate carnivore” nature of his own pets. Dissatisfied with conventional options, he set out to develop a high-meat, biologically appropriate formula, which eventually evolved into the award-winning 42 Series.​

Designed to replicate the “Ancestral Blueprint” of wild felines, the Bite of Wild 42 Series (including the P42 High Meats, F42 6-Fish recipes, and K42 Kitten Formula) is engineered for the “Tiger Physique.” The series boasts industry-leading specifications:​

1. 92% Animal Raw Materials: Providing pure biological fuel.​
2. 42% High Crude Protein: The gold standard for lean muscle and vitality.​
3. 0% Grain & Pork: Eliminating common allergens to ensure peak digestive health.​

Bite of Wild caters to the “obligate carnivore” nature of cats, proving that high-performance nutrition can be both scientifically precise and naturally sourced.​

A New Era for the Pan-Asian Pet Market​

The success of MR.VET and Bite of Wild at the Global Pet Expo signals a broader revolution within the Asian pet market—a transition from “basic feeding” to “scientific nurturing.”​

“Winning two Orange Dot Awards in Biotech and Nutrition is a powerful validation of our commitment to elevating pet health standards across the Asian market,” said Steve Bui, co-founder of the brands, during the Orlando ceremony. “It proves that by merging global scientific breakthroughs with deep regional insights, we can lead the world in both market scale and technological sophistication.”​

As MR.VET continues to expand its footprint across the Pan-Asian region and beyond, its mission remains clear: to provide pets with “the right care made easy”—backed by science and proven by millions of satisfied owners. The revolution in pet health has arrived, led by the “Tiger Physique” of Bite of Wild and the biotech-driven precision of MR.VET.

Hashtag: #MRVET

The issuer is solely responsible for the content of this announcement.

The proposed tender offer price is ¥4,750 a share. That figure carries an unusual wrinkle: Reuters reported it stood 4.7% below Taiyo’s last closing price, reflecting how market speculation had already lifted the stock, while the joint company release framed the offer as carrying a steep premium to unaffected average prices before the bidding process became public and before activist-related filings stirred the shares. The contrast underlines how Japan’s take-private deals are increasingly playing out in markets already primed by rumour, activism and expectations of strategic change.

Taiyo is not a household consumer name, but it sits in businesses that have become more visible to global investors. The group is a leading producer of solder resist and other materials used in printed circuit boards and semiconductor packaging substrates, while also operating a medical and pharmaceutical arm that makes prescription drugs and provides contract development and manufacturing services. In its own long-term planning, Taiyo has pointed to growth opportunities from generative AI, data centres and communications infrastructure on the electronics side, alongside structural reform and expansion in contract manufacturing for pharmaceuticals.

That mix helps explain why KKR sees room for a private-market strategy. Taiyo said privatisation would allow it to pursue long-term investments and quicker decision-making with less pressure from the public market. The company’s “Beyond Imagination 2030” plan targets a rise in net sales to ¥180 billion by fiscal 2031 from ¥119 billion in fiscal 2025, while operating income is targeted to more than double to ¥47 billion from ¥22 billion. Management has also been trying to improve capital efficiency after sustained dialogue with shareholders, including a focus on profitability in the medical and pharmaceuticals unit and a review of portfolio positioning across the group.

For KKR, the Taiyo bid fits a broader pattern in Japan. The firm said it has been investing in the country for two decades and manages more than $20 billion there. Its existing investments span semiconductor equipment, pharmaceuticals, information technology and logistics, sectors where global funds have been seeking companies with specialised technology, export potential or scope for operational overhaul. Taiyo gives KKR exposure to electronics materials tied to advanced manufacturing as well as a pharmaceuticals platform that could benefit from demand for contract manufacturing and stable domestic drug supply.

The shareholder line-up behind the offer is also notable. DIC, Taiyo’s largest shareholder, and Kowa, which is affiliated with the founding family, have agreed to sell through a share consolidation and buyback process after the tender offer is completed. The founding family plans to reinvest in the KKR-managed vehicle that will own Taiyo after privatisation. Oasis Management, long known for active positions in Japan, has separately agreed to tender shares representing about 15.62% of the company. That combination reduces execution risk and suggests the deal has been designed to balance continuity with outside capital and governance pressure.

Still, the transaction comes with questions that investors and analysts will watch closely. A take-private at a headline valuation above ¥500 billion will invite scrutiny over whether minority holders are being offered enough upside after the stock’s sharp re-rating. The tender offer has yet to begin formally and remains subject to customary conditions, including regulatory approvals. Any delays or shifts in market conditions could test sentiment, especially at a time when deal financing and foreign buyouts in Japan are being judged against a higher bar on governance, transparency and shareholder treatment.

Taiyo’s business profile gives the story wider significance than a conventional chemicals buyout. Its electronics arm remains the core earnings driver, but the medical and pharmaceuticals business has been gaining attention as order volumes rise in contract manufacturing and as the group tries to lift margins. Taiyo’s own targets show electronics sales climbing to ¥128 billion by fiscal 2031 and medical and pharmaceuticals sales to ¥43 billion, with the latter expected to deliver a marked improvement in profitability. That combination of steady industrial demand and a healthcare growth angle is the sort of hybrid case private equity firms have been seeking across Japan’s listed mid-cap sector.